2013

FASN Anti-Tumor Candidate in Clinical Development Menlo Park, California, December 4, 2013. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing […]

Menlo Park, California, November 21, 2013. 3-V Biosciences, Inc. (3‐V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways

3-V’s Small Molecule Tumor Metabolism Inhibitor Demonstrates Single-Agent Activity; Halts Tumor Growth and Induces Tumor Regression Menlo Park, California, October

Menlo Park, California, June 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology